Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05352750 · ClinicalTrials.gov registry record · Phase 1
Phase 1 Study of SON-1010 in Adult Patients With Advanced Solid Tumors
A Phase 1 study of Advanced Solid Tumor and Soft Tissue Sarcoma Adult, sponsored by Sonnet BioTherapeutics.
- Active
- Registry status
- Phase 1
- Development phase
- 42
- Enrollment target
- 1
- Study location
NCT05352750: Active Phase 1 study of Advanced Solid Tumor and Soft Tissue Sarcoma Adult, sponsored by Sonnet BioTherapeutics.
NCT05352750 is a Phase 1 study of Advanced Solid Tumor and Soft Tissue Sarcoma Adult that is active but no longer recruiting, run by Sonnet BioTherapeutics. The registered enrollment target is 42 participants, below the 193-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target (78% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05352750, a Phase 1 study of Advanced Solid Tumor and Soft Tissue Sarcoma Adult, is active but no longer recruiting, sponsored by Sonnet BioTherapeutics.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 42 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a Phase 1, first-in-human, open-label, adaptive-design outpatient study to assess the safety, tolerability, and PK/PD of SON-1010 administered to patients with advanced solid tumors.
Primary Outcome
Number of participants with treatment-related adverse events as assessed by CTCAE v5.0
Conditions Studied
Interventions
- BIOLOGICAL SON-1010
Study Locations (1)
California
- Sarcoma Oncology Center - Santa Monica
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2022-04-20 |
| Est. Completion | 2026-06-30 |
| Phase | Phase 1 |
What the registry record for NCT05352750 still lists
NCT05352750 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 42 participants, a relatively small participant target, below the 193-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target (78% lower).
The record links to 2 conditions, with Advanced Solid Tumor appearing as the primary indexed condition, and to 1 intervention - of which SON-1010 is the first listed.
NCT05352750 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT05352750 about?
NCT05352750 is a clinical study titled "Phase 1 Study of SON-1010 in Adult Patients With Advanced Solid Tumors". This is a Phase 1, first-in-human, open-label, adaptive-design outpatient study to assess the safety, tolerability, and PK/PD of SON-1010 administered to patients with advanced solid tumors.
What is the current status of trial NCT05352750?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 42 participants. The study started on 2022-04-20. Estimated completion is 2026-06-30.
What conditions does trial NCT05352750 study?
This clinical trial studies the following conditions: Advanced Solid Tumor, Soft Tissue Sarcoma Adult.
What interventions are being tested in trial NCT05352750?
The interventions under investigation include: SON-1010 (BIOLOGICAL).
Who is sponsoring clinical trial NCT05352750?
This trial is sponsored by Sonnet BioTherapeutics, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05352750 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Solid Tumor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05352750's enrollment target sits among peer trials
42 167th of 189 higher than 21 of 189 other Advanced Solid Tumor trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Advanced Solid Tumor trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
PM14 Administered Intravenously to Patients with Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study of EP0031 in Patients With Advanced RET-altered Malignancies
RECRUITING · Phase 1
-
Study of AVZO-021 in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
A First-in-Human Study of YL217 in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02852213 · 42 participants · Phase 1
A Single-Stage, Adaptive, Open-label, Dose Escalation Safety and Efficacy Study of AADC Deficiency in Pediatric Patients
- NCT03136146 · 42 participants · Phase 2
Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia
- NCT03178149 · 42 participants · Phase 1
A Study of the Safety and Tolerability of ASP7317 in Senior Adults Who Are Losing Their Clear, Sharp Central Vision Due to Geographic Atrophy Secondary to Dry Age-related Macular Degeneration
- NCT03663530 · 42 participants · NA
Circadian Misalignment and Energy Balance
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI